PURPOSE: Neoadjuvant pemetrexed plus cisplatin was administered, followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT), to assess the feasibility and efficacy of trimodality therapy in stage I to III malignant pleural mesothelioma. PATIENTS AND METHODS: Requirements included stage T1-3 N0-2 disease, no prior surgical resection, adequate organ function (including predicted postoperative forced expiratory volume in 1 second > or = 35%), and performance status 0 to 1. Patients received pemetrexed 500 mg/m(2) plus cisplatin 75 mg/m(2) for four cycles. Patients without disease progression underwent EPP followed by RT (54 Gy). The primary end point was pathologic complete response (pCR) rate. RESULTS: Seventy-seven patients received chemotherapy. All four cycles were administered to 83% of patients. The radiologic response rate was 32.5% (95% CI, 22.2 to 44.1). Fifty-seven patients proceeded to EPP, which was completed in 54 patients. Three pCRs were observed (5% of EPP). Forty of 44 patients completed irradiation. Median survival in the overall population was 16.8 months (95% CI, 13.6 to 23.2 months; censorship, 33.8%). Patients completing all therapy had a median survival of 29.1 months and a 2-year survival rate of 61.2%. Radiologic response of complete or partial response was associated with a median survival of 26.0 months compared with 13.9 months for patients with stable disease or progressive disease (P = .05). CONCLUSION: This multicenter trial showed that trimodality therapy with neoadjuvant pemetrexed plus cisplatin is feasible with a reasonable long-term survival rate, particularly for patients who completed all therapy. Radiologic response to chemotherapy, but not sex, histology, disease stage, or nodal status, was associated with improved survival.
PURPOSE: Neoadjuvant pemetrexed plus cisplatin was administered, followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT), to assess the feasibility and efficacy of trimodality therapy in stage I to III malignant pleural mesothelioma. PATIENTS AND METHODS: Requirements included stage T1-3 N0-2 disease, no prior surgical resection, adequate organ function (including predicted postoperative forced expiratory volume in 1 second > or = 35%), and performance status 0 to 1. Patients received pemetrexed 500 mg/m(2) plus cisplatin 75 mg/m(2) for four cycles. Patients without disease progression underwent EPP followed by RT (54 Gy). The primary end point was pathologic complete response (pCR) rate. RESULTS: Seventy-seven patients received chemotherapy. All four cycles were administered to 83% of patients. The radiologic response rate was 32.5% (95% CI, 22.2 to 44.1). Fifty-seven patients proceeded to EPP, which was completed in 54 patients. Three pCRs were observed (5% of EPP). Forty of 44 patients completed irradiation. Median survival in the overall population was 16.8 months (95% CI, 13.6 to 23.2 months; censorship, 33.8%). Patients completing all therapy had a median survival of 29.1 months and a 2-year survival rate of 61.2%. Radiologic response of complete or partial response was associated with a median survival of 26.0 months compared with 13.9 months for patients with stable disease or progressive disease (P = .05). CONCLUSION: This multicenter trial showed that trimodality therapy with neoadjuvant pemetrexed plus cisplatin is feasible with a reasonable long-term survival rate, particularly for patients who completed all therapy. Radiologic response to chemotherapy, but not sex, histology, disease stage, or nodal status, was associated with improved survival.
Authors: Aaron M Allen; Maria Czerminska; Pasi A Jänne; David J Sugarbaker; Raphael Bueno; Jay R Harris; Laurence Court; Elizabeth H Baldini Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-01 Impact factor: 7.038
Authors: Hasan Fevzi Batirel; Muzaffer Metintas; Hale Basak Caglar; Bedrettin Yildizeli; Tunc Lacin; Korkut Bostanci; Asli Gul Akgul; Serdar Evman; Mustafa Yuksel Journal: J Thorac Oncol Date: 2008-05 Impact factor: 15.609
Authors: Federico Rea; Giuseppe Marulli; Luigi Bortolotti; Cristiano Breda; Adolfo Gino Favaretto; Lucio Loreggian; Francesco Sartori Journal: Lung Cancer Date: 2007-04-02 Impact factor: 5.705
Authors: Raja M Flores; Lee M Krug; Kenneth E Rosenzweig; Ennapadam Venkatraman; Alain Vincent; Robert Heelan; Tim Akhurst; Valerie W Rusch Journal: J Thorac Oncol Date: 2006-05 Impact factor: 15.609
Authors: David J Sugarbaker; William G Richards; Gavin J Gordon; Lingsheng Dong; Assunta De Rienzo; Gautam Maulik; Jonathan N Glickman; Lucian R Chirieac; Mor-Li Hartman; Bruce E Taillon; Lei Du; Pascal Bouffard; Stephen F Kingsmore; Neil A Miller; Andrew D Farmer; Roderick V Jensen; Steven R Gullans; Raphael Bueno Journal: Proc Natl Acad Sci U S A Date: 2008-02-26 Impact factor: 11.205
Authors: W Weder; R A Stahel; J Bernhard; S Bodis; P Vogt; P Ballabeni; D Lardinois; D Betticher; R Schmid; R Stupp; H B Ris; M Jermann; W Mingrone; A D Roth; A Spiliopoulos Journal: Ann Oncol Date: 2007-04-11 Impact factor: 32.976
Authors: Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2008-02-14 Impact factor: 5.209
Authors: Lee M Krug; Tao Dao; Andrew B Brown; Peter Maslak; William Travis; Sara Bekele; Tatyana Korontsvit; Victoria Zakhaleva; Jedd Wolchok; Jianda Yuan; Hao Li; Leslie Tyson; David A Scheinberg Journal: Cancer Immunol Immunother Date: 2010-06-08 Impact factor: 6.968
Authors: Mehmet Ali Bedirhan; Levent Cansever; Adalet Demir; Süleyman Ceyhan; Hasan Akın; Halide Nur Urer; Aysun Olçmen; Celalettin Kocatürk; Ibrahim Dinçer Journal: J Thorac Dis Date: 2013-08 Impact factor: 2.895
Authors: Daniel R Gomez; David S Hong; Pamela K Allen; James S Welsh; Reza J Mehran; Anne S Tsao; Zhongxing Liao; Stephen D Bilton; Ritsuko Komaki; David C Rice Journal: J Thorac Oncol Date: 2013-02 Impact factor: 15.609